April 26th 2024
New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.
Model that Decriminalized Drugs, Invests Savings Shows Reduction in HIV Transmission
January 28th 2022The study authors focused on eastern Europe and central Asia in their model, which included 4 scenarios for decriminalizing drug use and investing the savings into HIV transmission-reduction strategies.
Read More
Ready, Set, Cabenuva: Implementing Cabotegravir/Rilpivirine
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Read More